Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMGNNASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shs40 shsMLTXMoonLake Immunotherapeutics$39.67-2.2%$42.53$36.52▼$58.26$2.54B1.31334,706 shs423,849 shsThe 10 Best Stocks to Own: Spring 2025Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMGNImmunoGen0.00%0.00%0.00%0.00%0.00%MLTXMoonLake Immunotherapeutics+1.15%+4.94%-4.02%-22.95%-21.96%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMGNImmunoGenN/AN/AN/AN/AN/AN/AN/AN/AMLTXMoonLake Immunotherapeutics2.1934 of 5 stars3.52.00.00.02.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMGNImmunoGen 0.00N/AN/AN/AMLTXMoonLake Immunotherapeutics 3.00Buy$80.50102.92% UpsideCurrent Analyst Ratings BreakdownLatest MLTX and IMGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025MLTXMoonLake ImmunotherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$67.002/27/2025MLTXMoonLake ImmunotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$82.00 ➝ $73.002/27/2025MLTXMoonLake ImmunotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$62.00 ➝ $66.002/27/2025MLTXMoonLake ImmunotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.001/17/2025MLTXMoonLake ImmunotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$62.00 ➝ $82.001/10/2025MLTXMoonLake ImmunotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMGNImmunoGen$287.61M28.91N/AN/A$0.71 per share43.99MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$8.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMGNImmunoGen-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/AMLTXMoonLake Immunotherapeutics-$36.01M-$1.89N/AN/AN/AN/A-15.54%-15.09%5/6/2025 (Estimated)Latest MLTX and IMGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2025Q4 2024MLTXMoonLake Immunotherapeutics-$0.63-$0.72-$0.09-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMGNImmunoGenN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMGNImmunoGen0.135.705.65MLTXMoonLake ImmunotherapeuticsN/A25.5125.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMGNImmunoGen90.50%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipIMGNImmunoGen5.07%MLTXMoonLake Immunotherapeutics12.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMGNImmunoGen277266.26 million252.76 millionOptionableMLTXMoonLake Immunotherapeutics264.01 million56.22 millionOptionableMLTX and IMGN HeadlinesRecent News About These CompaniesMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 2.9% - Still a Buy?March 19, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Now Covered by Royal Bank of CanadaMarch 19, 2025 | marketbeat.comRBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform RecommendationMarch 18, 2025 | msn.comMoonLake Immunotherapeutics initiated with an Outperform at RBC CapitalMarch 18, 2025 | markets.businessinsider.comRBC Capital Initiates a Buy Rating on MoonLake Immunotherapeutics (MLTX)March 18, 2025 | markets.businessinsider.comMoonLake Immunotherapeutics Advances Clinical Trials in 2024March 15, 2025 | tipranks.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc.March 14, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Hits New 52-Week Low - What's Next?March 11, 2025 | marketbeat.comCandriam S.C.A. Sells 11,524 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)March 8, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Buy" by BrokeragesMarch 3, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for MLTX Q1 Earnings?March 3, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for MLTX Q1 Earnings?March 3, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Position Decreased by Y Intercept Hong Kong LtdMarch 2, 2025 | marketbeat.comBrokers Offer Predictions for MLTX Q2 EarningsMarch 1, 2025 | marketbeat.comWedbush Has Negative Forecast for MLTX Q1 EarningsMarch 1, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target Cut to $73.00 by Analysts at The Goldman Sachs GroupFebruary 28, 2025 | marketbeat.comMoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC WainwrightFebruary 28, 2025 | marketbeat.comNeedham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00February 28, 2025 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Announces Quarterly Earnings ResultsFebruary 27, 2025 | marketbeat.comMoonLake Immunotherapeutics: Buy Rating Backed by Promising SLK Data and Strong Financial PositionFebruary 27, 2025 | tipranks.comMoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on ThursdayFebruary 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLTX and IMGN Company DescriptionsImmunoGen NASDAQ:IMGNImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.MoonLake Immunotherapeutics NASDAQ:MLTX$39.67 -0.91 (-2.24%) Closing price 04:00 PM EasternExtended Trading$39.62 -0.05 (-0.13%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
